Table 2 Patient characteristics at baseline (patients treated at the MTD)

From: Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer

Characteristic

Value

No. of patients

29

Median age (range) (years)

57 (40–73)

Sex, n (%)

 Male

25 (86)

 Female

4 (14)

Primary tumour site, n (%)

 Colon

15 (52)

 Rectum

9 (31)

 Rectosigmoid

5 (17)

WHO performance status, n (%)

 0

15 (52)

 1

11 (38)

 2

1 (3)

 Unknown

2 (7)

Prior surgical resection, n (%)

 Radical

9 (31)

 Palliative

10 (34)

 Defunctioned only

2 (7)

 None

8 (28)

No. of measurable lesions (%)

 1

1 (3)

 2

7 (24)

3

21 (72)

  1. MTD=maximum tolerated dose; WHO=World Health Organization.